A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

1 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-24

Study Completion Date

2022-05-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the efficacy and safety of alectinib in participants with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors other than lung cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

NCT03456076

Carcinoma, Non-Small-Cell Lung

ACTIVE_NOT_RECRUITING PHASE3

A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)

NCT01871805

Non-Small Cell Lung Cancer

COMPLETED PHASE1/PHASE2

Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns

NCT04351334

Non-Small-Cell Lung Carcinoma

COMPLETED

Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

NCT02604342

Non-small Cell Lung Cancer

COMPLETED PHASE3

ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer

NCT03445000

Non-small Cell Lung Cancer Non-small Cell Lung Cancer Metastatic Non-small Cell Lung Cancer Recurrent

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasms Colorectal Neoplasms Melanoma Pancreatic Neoplasms Sarcoma Ovarian Neoplasms Brain Neoplasms Thyroid Neoplasms Neuroendocrine Tumors Cholangiocarcinoma Salivary Gland Neoplasms Head and Neck Neoplasms Thyroid Cancer, Papillary Lymphoma, Large-Cell, Anaplastic Neoplasms by Site Respiratory Tract Neoplasms Thoracic Neoplasms Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Central Nervous System

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ALK-positive Solid Tumors

Participants with locally advanced or metastatic ALK-positive tumors will receive alectinib twice daily (BID) until disease progression, unacceptable toxicity, death, or withdrawal from the study for any reason.

Group Type EXPERIMENTAL

Alectinib

Intervention Type DRUG

Participants will receive 600 mg oral alectinib BID until disease progression, unacceptable toxicity, withdrawal from treatment, or death.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Alectinib

Participants will receive 600 mg oral alectinib BID until disease progression, unacceptable toxicity, withdrawal from treatment, or death.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Alecensa

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed ALK-positive locally-advanced or metastatic solid tumor excluding lung cancer
* ALK-positive tumor as per Foundation Medicine, Inc (FMI) next-generation sequencing (NGS) (NGS F1CDx, F1LCDx, or F1HEME) or per local accredited laboratory using validated NGS testing of tumor tissue or peripheral blood
* No alternative effective standard therapy available, or standard therapy considered unsuitable or intolerable to the participant
* Other cancer therapies are allowed, including investigational drugs, if any treatment-related toxicities (excluding alopecia) have resolved to grade \</= 1 or to laboratory values as defined by the protocol
* Measurable disease at baseline as assessed by the Investigator per RECIST v1.1 or RANO criteria (for participants with primary CNS tumors)
* Life expectancy of at least 12 weeks
* Eastern cooperative oncology group (ECOG) performance status of 0-2
* Adequate hemataologic, hepatic, and renal function
* Participants with primary central nervous system (CNS) tumors are available
* Participants with brain or leptomeningeal metastasis are allowed in the study if asymptomatic and if they meet additional criteria as defined by the protocol
* Willingness to comply with study procedures
* Willingness to comply with home-base approach and visits by Mobile Nurses
* Ability to swallow alectinib capsules intact
* Women of childbearing potential must test negative for pregnancy at screening and prior to the first dose of study drug
* Women of childbearing potential must agree to remain abstinent or use contraceptive methods as defined by the protocol and refrain from donating eggs during the treatment period and for at least 90 days after the last dose of alectinib
* Men must agree to remain abstinent or use contraceptive methods as defined by the protocol and refrain from donating sperm during the treatment period and for at least 90 days after the last dose of alectinib

Exclusion Criteria

* Pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the final dose of alectinib
* Lung Cancer
* Patients with one of the following ALK point mutations: I1171X, G1202R, V1180L
* Prior therapy with an ALK inhibitor
* Liver disease as described in the protocol
* Known HIV, hepatitis B, or hepatitis C (HCV) infection
* Patients with symptomatic bradycardia
* Patients with symptomatic or unstable brain metastasis; patients with primary CNS tumors are allowed
* Malabsorption syndrome or any other condition that would interfere with enteral absorption
* Incomplete recovery from any surgery prior to treatment
* Any other malignancies within 5 years prior to enrollment, except for those described in the protocol
* Any serious medical condition or abnormality in clinical laboratory tests that, in the Investigator's judgment, precludes the patient's safe participation in and completion of the study
* History of hypersensitivity to any of the ingredients in the alectinib drug formulation

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No